Hope In A Pill
A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
April 6, 2009 Cover
Volume 87, Issue 14
A crop of small-molecule drugs in development could double the treatment options for people with multiple sclerosis in coming years
Credit:
Biological Chemistry
Genes Take A Back Seat
Epigenetics, the molecular framework that controls genes’ expression, takes its cues from both nature and nurture
Biosimilars Debate
Rival bills in Congress differ in how long innovators can enjoy market exclusivity
-
Orchestrating Genetic Expression
Epigenetic modifications alter chromatin landscape, turn genes on and off
-
DCAT Week Ennui
Too much defense and not enough offense at drug industry event
-
A Climate of Change
Diplomats begin working out new global treaty to curb greenhouse gas emissions
ADVERTISEMENT
Science Concentrates
The First Four
The founding generation of epigenetics-based drugs combine promise and peril
